InSysBio to present at ICSB 2018

events
Conference
October 24, 2018

October 24, 2018

InSysBio announces their participation at 19th International Conference on Systems Biology (ICSB 2018) to be held October 28th to November 1st, 2018 in Lyon, France. Two InSysBio posters will be presented:

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

May 2024
MoTuWeThFrSaSu
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1. 16 May 2024 18:06 InSysBio to take part in PAGE 2024 InSysBio announces its participation in the Thirty-second PAGE Meeting which is to be held from 26-28 June, 2024, at the Ergife Hotel in Rome, Italy. InSysBio will conduct a workshop on Immune Response Template (IRT), present its modeling services & software to optimize drug development at the Booth #15 and 5 posters in frames of the Meeting
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
  
Upcoming Events
25.06
InSysBio to hold a workshop on IRT at PAGE 2024
26.06
InSysBio to take part in PAGE 2024
Tags
Latest News
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator
06.04
InSysBio to release Immune Response Template 3.6.2 for QSP modeling
16.01
InSysBio team to publish the new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study”